{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:20:04Z","timestamp":1783675204547,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02388-y","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:32:45Z","timestamp":1783668765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 1"],"prefix":"10.1007","volume":"28","author":[{"given":"Tanawat","family":"Attachaipanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin K","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"15","key":"2388_CR1","doi-asserted-by":"publisher","first-page":"e1841","DOI":"10.4244\/EIJ-D-17-00723","volume":"13","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Harrington RA, Stone GW, Steg G, Gibson CM, Hamm CW, et al. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018;13(15):e1841\u20139.","journal-title":"EuroIntervention"},{"issue":"13","key":"2388_CR2","first-page":"e771","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771\u2013862.","journal-title":"Circulation"},{"issue":"1 Suppl","key":"2388_CR3","doi-asserted-by":"publisher","first-page":"s64","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):s64\u201394.","journal-title":"Chest"},{"issue":"6","key":"2388_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"R Mehran","year":"2011","unstructured":"Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv. 2011;4(6):654\u201364.","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"2388_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","volume":"51","author":"G Ndrepepa","year":"2008","unstructured":"Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Sch\u00f6mig A, Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2388_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3174\/ajnr.A2621","volume":"33","author":"HM Hussein","year":"2012","unstructured":"Hussein HM, Georgiadis AL, Qureshi AI. Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures. AJNR Am J Neuroradiol. 2012;33(7):1211\u201320.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"2388_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/labmed\/lmz014","volume":"50","author":"TZ Thompson","year":"2019","unstructured":"Thompson TZ, Kunak RL, Savage NM, Agarwal S, Chazelle J, Singh G. Intraoperative monitoring of heparin: Comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma Anti-Xa assay. Lab Med. 2019;50(4):348\u201356.","journal-title":"Lab Med"},{"issue":"7","key":"2388_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103(7):961\u20136.","journal-title":"Circulation"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.me.40.020189.000335","volume":"40","author":"TE Warkentin","year":"1989","unstructured":"Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med. 1989;40:31\u201344.","journal-title":"Annu Rev Med"},{"issue":"3","key":"2388_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMcp1411910","volume":"373","author":"A Greinacher","year":"2015","unstructured":"Greinacher A. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252\u201361.","journal-title":"N Engl J Med"},{"issue":"3","key":"2388_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0038-1642434","volume":"71","author":"E Young","year":"1994","unstructured":"Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71(3):300\u20134.","journal-title":"Thromb Haemost"},{"issue":"1","key":"2388_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","volume":"109","author":"MM Samama","year":"2003","unstructured":"Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003;109(1):1\u201311.","journal-title":"Thromb Res"},{"issue":"2 Suppl","key":"2388_CR13","doi-asserted-by":"publisher","first-page":"eS24","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):eS24\u2013e43.","journal-title":"Chest"},{"issue":"1","key":"2388_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0149-2918(02)85004-4","volume":"24","author":"TD Gladwell","year":"2002","unstructured":"Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002;24(1):38\u201358.","journal-title":"Clin Ther"},{"issue":"6","key":"2388_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1161\/01.CIR.59.6.1105","volume":"59","author":"K Davis Jr.","year":"1979","unstructured":"Davis K, Kennedy JW, Kemp HG Jr., Judkins MP, Gosselin AJ, Killip T. Complications of coronary arteriography from the Collaborative Study of Coronary Artery Surgery (CASS). Circulation. 1979;59(6):1105\u201312.","journal-title":"Circulation"},{"issue":"16","key":"2388_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJM197304192881607","volume":"288","author":"WJ Walker","year":"1973","unstructured":"Walker WJ, Mundall SL, Broderick HG, Prasad B, Kim J, Ravi JM. Systemic heparinization for femoral percutaneous coronary arteriography. N Engl J Med. 1973;288(16):826\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2388_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0009-9260(76)80078-5","volume":"27","author":"JF Silverman","year":"1976","unstructured":"Silverman JF, Wexler L. Complications of percutaneous transfemoral coronary arteriography. Clin Radiol. 1976;27(3):317\u201321.","journal-title":"Clin Radiol"},{"issue":"4","key":"2388_CR18","first-page":"321","volume":"38","author":"M Gharakhani","year":"2013","unstructured":"Gharakhani M, Emami F. Effect of Heparin Administration during Coronary Angiography on Vascular or Peripheral Complications: A Single-Blind Randomized Controlled Clinical Trial. Iran J Med Sci. 2013;38(4):321\u20136.","journal-title":"Iran J Med Sci"},{"issue":"3","key":"2388_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4244\/EIJV3I3A63","volume":"3","author":"A Tandar","year":"2007","unstructured":"Tandar A, Lehman CM, Rodgers GM, Meredith KG, Muhlestein JB, Barry WH, et al. Activation of coagulation during routine diagnostic coronary angiography. EuroIntervention. 2007;3(3):345\u20139.","journal-title":"EuroIntervention"},{"issue":"22","key":"2388_CR20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/j.jcin.2019.07.043","volume":"12","author":"I Bernat","year":"2019","unstructured":"Bernat I, Aminian A, Pancholy S, Mamas M, Gaudino M, Nolan J, et al. Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. JACC Cardiovasc Interv. 2019;12(22):2235\u201346.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"2388_CR21","doi-asserted-by":"publisher","first-page":"e007386","DOI":"10.1161\/CIRCINTERVENTIONS.119.007386","volume":"12","author":"Y Sandoval","year":"2019","unstructured":"Sandoval Y, Bell MR, Gulati R. Transradial artery access complications. Circ Cardiovasc Interv. 2019;12(11):e007386.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"2388_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.amjcard.2016.08.007","volume":"118","author":"O Maden","year":"2016","unstructured":"Maden O, Kafes H, Balci KG, Tola M, Sel\u00e7uk MT, Burak C, et al. Relation between end-procedural activated clotting time values and radial artery occlusion rate with standard fixed-dose heparin after transradial cardiac catheterization. Am J Cardiol. 2016;118(10):1455\u20139.","journal-title":"Am J Cardiol"},{"issue":"9","key":"2388_CR23","doi-asserted-by":"publisher","first-page":"e000035","DOI":"10.1161\/HCV.0000000000000035","volume":"11","author":"PJ Mason","year":"2018","unstructured":"Mason PJ, Shah B, Tamis-Holland JE, Bittl JA, Cohen MG, Safirstein J, et al. An Update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: A scientific statement from the American Heart Association. Circ Cardiovasc Interv. 2018;11(9):e000035.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"2388_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11239-009-0352-0","volume":"29","author":"H Feray","year":"2010","unstructured":"Feray H, Izgi C, Cetiner D, Men EE, Saltan Y, Baltay A, Kahraman R. Effectiveness of enoxaparin for prevention of radial artery occlusion after transradial cardiac catheterization. J Thromb Thrombolysis. 2010;29(3):322\u20135.","journal-title":"J Thromb Thrombolysis"},{"issue":"22","key":"2388_CR25","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.jcin.2018.08.009","volume":"11","author":"GN Hahalis","year":"2018","unstructured":"Hahalis GN, Leopoulou M, Tsigkas G, Xanthopoulou I, Patsilinakos S, Patsourakos NG, et al. Multicenter randomized evaluation of high versus standard heparin dose on incident radial arterial occlusion after transradial coronary angiography: The spirit of artemis study. JACC Cardiovasc Interv. 2018;11(22):2241\u201350.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"2388_CR26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jacc.2011.09.077","volume":"59","author":"NH Pijls","year":"2012","unstructured":"Pijls NH, Sels JW. Functional measurement of coronary stenosis. J Am Coll Cardiol. 2012;59(12):1045\u201357.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2388_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.15420\/icr.2017:13:2","volume":"12","author":"S Achenbach","year":"2017","unstructured":"Achenbach S, Rudolph T, Rieber J, Eggebrecht H, Richardt G, Schmitz T, et al. Performing and interpreting fractional flow reserve measurements in clinical practice: An expert consensus document. Interv Cardiol. 2017;12(2):97\u2013109.","journal-title":"Interv Cardiol"},{"issue":"7","key":"2388_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.amjcard.2007.04.057","volume":"100","author":"R Valencia","year":"2007","unstructured":"Valencia R, Price MJ, Sawhney N, Lee SS, Wong GB, Gollapudi RR, et al. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial). Am J Cardiol. 2007;100(7):1099\u2013102.","journal-title":"Am J Cardiol"},{"issue":"16","key":"2388_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jacc.2008.07.026","volume":"52","author":"E Stabile","year":"2008","unstructured":"Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008;52(16):1293\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3 Pt B","key":"2388_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.carrev.2017.08.007","volume":"19","author":"F Boccalandro","year":"2018","unstructured":"Boccalandro F, Dhindsa M, Subramaniyam P, Mok M. Feasibility of coronary fractional flow reserve with dual anti-platelet therapy in low risk coronary lesions without systemic anticoagulation-results of the SMART-FFR study. Cardiovasc Revasc Med. 2018;19(3 Pt B):343\u20137.","journal-title":"Cardiovasc Revasc Med"},{"issue":"3","key":"2388_CR31","first-page":"e18","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC\/AHA\/SCAI Guideline for coronary artery revascularization: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(3):e18\u2013114.","journal-title":"Circulation"},{"issue":"2","key":"2388_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"20","key":"2388_CR33","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1093\/eurheartj\/ehq330","volume":"31","author":"S Schulz","year":"2010","unstructured":"Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(20):2482\u201391.","journal-title":"Eur Heart J"},{"issue":"10","key":"2388_CR34","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1056\/NEJMoa052711","volume":"355","author":"G Montalescot","year":"2006","unstructured":"Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1006\u201317.","journal-title":"N Engl J Med"},{"issue":"7","key":"2388_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853\u201363.","journal-title":"JAMA"},{"issue":"7","key":"2388_CR36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJMoa0802944","volume":"359","author":"A Kastrati","year":"2008","unstructured":"Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, B\u00fcttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688\u201396.","journal-title":"N Engl J Med"},{"issue":"12","key":"2388_CR37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.2010.1320","volume":"304","author":"PG Steg","year":"2010","unstructured":"Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial. JAMA. 2010;304(12):1339\u201349.","journal-title":"JAMA"},{"issue":"11","key":"2388_CR38","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Frigoli E, Leonardi S, Rothenb\u00fchler M, Gagnor A, Calabr\u00f2 P, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373(11):997\u20131009.","journal-title":"N Engl J Med"},{"issue":"3","key":"2388_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4244\/EIJV6I3A67","volume":"6","author":"O Bertel","year":"2010","unstructured":"Bertel O, Ramsay D, Wettstein T, Kurz DJ, Stettler I, Straumann E, et al. Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). EuroIntervention. 2010;6(3):407\u201312.","journal-title":"EuroIntervention"},{"issue":"23","key":"2388_CR40","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jacc.2007.01.093","volume":"49","author":"CM Gibson","year":"2007","unstructured":"Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49(23):2238\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2388_CR41","first-page":"45","volume":"292","author":"JJ Ferguson","year":"2004","unstructured":"Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45\u201354.","journal-title":"JAMA"},{"issue":"9792","key":"2388_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","volume":"378","author":"G Montalescot","year":"2011","unstructured":"Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378(9792):693\u2013703.","journal-title":"Lancet"},{"issue":"21","key":"2388_CR43","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"GW Stone","year":"2006","unstructured":"Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"2388_CR44","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","volume":"365","author":"A Kastrati","year":"2011","unstructured":"Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365(21):1980\u20139.","journal-title":"N Engl J Med"},{"issue":"9784","key":"2388_CR45","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","volume":"377","author":"GW Stone","year":"2011","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377(9784):2193\u2013204.","journal-title":"Lancet"},{"issue":"23","key":"2388_CR46","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","volume":"369","author":"PG van Steg","year":"2013","unstructured":"Steg PG, van \u2018t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207\u201317.","journal-title":"N Engl J Med"},{"issue":"9957","key":"2388_CR47","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384(9957):1849\u201358.","journal-title":"Lancet"},{"issue":"13","key":"2388_CR48","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313(13):1336\u201346.","journal-title":"JAMA"},{"issue":"12","key":"2388_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, Fr\u00f6bert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"10366","key":"2388_CR50","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847\u201357.","journal-title":"Lancet"},{"issue":"38","key":"2388_CR51","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"11","key":"2388_CR52","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcin.2018.01.257","volume":"11","author":"DW Louis","year":"2018","unstructured":"Louis DW, Kennedy K, Lima FV, Pancholy SB, Abbott JD, Gordon P, Aronow HD. Association between maximal activated clotting time and major bleeding complications during transradial and transfemoral percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(11):1036\u201345.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"2388_CR53","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","volume":"152","author":"HD White","year":"2006","unstructured":"White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb\/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152(6):1042\u201350.","journal-title":"Am Heart J"},{"issue":"16","key":"2388_CR54","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","volume":"148","author":"B Bikdeli","year":"2023","unstructured":"Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, et al. Bivalirudin Versus heparin during PCI in NSTEMI: Individual patient data meta-analysis of large randomized trials. Circulation. 2023;148(16):1207\u201319.","journal-title":"Circulation"},{"issue":"21","key":"2388_CR55","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218\u201330.","journal-title":"N Engl J Med"},{"issue":"16","key":"2388_CR56","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","volume":"84","author":"GW Stone","year":"2024","unstructured":"Stone GW, Valgimigli M, Erlinge D, Han Y, Steg PG, Stables RH, et al. Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results. J Am Coll Cardiol. 2024;84(16):1512\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2388_CR57","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJMoa055443","volume":"354","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464\u201376.","journal-title":"N Engl J Med"},{"issue":"13","key":"2388_CR58","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519\u201330.","journal-title":"JAMA"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02388-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:01:54Z","timestamp":1783674114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02388-y","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Krittanawong is the founder of HumanX, a company that focuses on artificial intelligence in precision medicine and innovation in healthcare; he declares that his affiliation with HumanX is not a competing interest. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}